Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resista…

Blue Earth Therapeutics, a clinical-stage radiopharmaceutical company and University College London (UCL) today announced ...